Bausch + Lomb (NYSE:BLCO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Bausch + Lomb (NYSE:BLCO) released its quarterly earnings data on Wednesday. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02, Zacks reports. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. Bausch + Lomb’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.07) EPS.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Strong quarter and raised guidance — Q1 delivered 6% constant-currency revenue growth, adjusted EBITDA up 59% (adjusted EBITDA margin 16.1%), and management raised full-year revenue guidance to $5.42–$5.52B and adjusted EBITDA to $1.01–$1.06B.
• Pharma/dry-eye momentum — Pharmaceuticals grew 12% CC with MIEBO up ~33% and Xiidra up ~30% as the company shifts from launch to growth, driving meaningful revenue and margin leverage.
• Active pipeline and higher R&D investment — R&D spend rose ~15–17% while the company filed an NDA for LUMIFY Next, completed a CE submission for Silara, and began shipping PreserVision AREDS 3 and Blink Triple Care PF, highlighting commercialization progress.
• Contact lenses and premium mix driving margin — Contact lens revenue grew 5% with daily SiHy up ~23–25%, and premium products now represent 26% of U.S. sales (vs. 19% a year ago), supporting higher-margin mix and share gains.
• Surgical segment near-term headwinds — Surgical revenue rose just 1% as weather-related procedure disruptions, reimbursement pressures, and a U.S. surgical field-force rebuild caused short-term impact, though management expects sequential improvement.

Bausch + Lomb Stock Up 3.7%

BLCO traded up $0.56 during mid-day trading on Thursday, reaching $15.90. 744,069 shares of the stock were exchanged, compared to its average volume of 417,530. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.04 and a current ratio of 1.55. The stock has a market capitalization of $5.67 billion, a PE ratio of -15.59, a price-to-earnings-growth ratio of 0.66 and a beta of 0.65. The company has a 50 day moving average price of $16.69 and a two-hundred day moving average price of $16.51. Bausch + Lomb has a 1 year low of $10.83 and a 1 year high of $18.92.

Bausch + Lomb News Summary

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q1 beat and stronger operating results: Bausch + Lomb reported Q1 revenue of $1.244B (≈+9% YoY) and EPS of $0.08, beating consensus. Adjusted EBITDA was $189M (and $200M excluding acquired IPR&D), signaling margin improvement and healthier cash‑flow conversion. Read More.
• Positive Sentiment: Management raised 2026 guidance: Management lifted FY2026 revenue guidance to $5.42B–$5.52B and projected adjusted EBITDA of ~$1.01B–$1.06B, giving investors a clearer path to scaled margins and earnings improvement. The guidance bump is the main catalyst for the upward move in the stock. Read More.
• Neutral Sentiment: Pipeline and scientific visibility: Bausch + Lomb will present more than 40 scientific studies at ARVO 2026, highlighting R&D progress and supporting the company’s long‑term product and innovation story — positive for sentiment but longer-term in impact. Read More.
• Negative Sentiment: GAAP loss and negative margins remain: The company still reported a GAAP net loss attributable to Bausch + Lomb (~$71M in Q1) and a negative net margin (~-7.1%), so while adjusted metrics are improving, GAAP profitability and full normalization of margins remain risks to monitor. Read More.

Insiders Place Their Bets

In other news, EVP A Robert D. Bailey acquired 14,600 shares of the business’s stock in a transaction on Friday, March 6th. The shares were purchased at an average cost of $17.15 per share, with a total value of $250,390.00. Following the acquisition, the executive vice president directly owned 231,890 shares of the company’s stock, valued at $3,976,913.50. The trade was a 6.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sam Eldessouky acquired 4,000 shares of the business’s stock in a transaction on Friday, March 6th. The shares were purchased at an average cost of $17.13 per share, for a total transaction of $68,520.00. Following the completion of the acquisition, the chief financial officer directly owned 403,130 shares in the company, valued at approximately $6,905,616.90. The trade was a 1.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 33,300 shares of company stock valued at $570,868 in the last three months. 1.45% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cetera Investment Advisers boosted its holdings in shares of Bausch + Lomb by 3.9% in the 4th quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock worth $320,000 after buying an additional 711 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Bausch + Lomb by 38.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,757 shares of the company’s stock worth $64,000 after buying an additional 1,039 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Bausch + Lomb by 104.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after buying an additional 1,136 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Bausch + Lomb by 31.2% in the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after buying an additional 1,403 shares during the last quarter. Finally, Woodline Partners LP boosted its holdings in shares of Bausch + Lomb by 0.5% in the 1st quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock worth $4,536,000 after buying an additional 1,436 shares during the last quarter. 11.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BLCO shares. HC Wainwright lifted their price objective on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Royal Bank Of Canada lifted their price objective on shares of Bausch + Lomb from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Tuesday, January 27th. The Goldman Sachs Group restated a “neutral” rating and set a $19.00 price target on shares of Bausch + Lomb in a research note on Friday, January 9th. Stifel Nicolaus set a $16.00 price target on shares of Bausch + Lomb in a research note on Thursday, February 19th. Finally, Evercore set a $18.00 price target on shares of Bausch + Lomb and gave the company an “in-line” rating in a research note on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bausch + Lomb has an average rating of “Hold” and an average price target of $18.08.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.